Lin Yu-En, Lin Hui-Ping, Lu Kuan-Hung, Huang Yun-Ju, Panyod Suraphan, Liu Wei-Ting, Lu Yun-Sheng, Chen Mei-Hsing, Sheen Lee-Yan
Institute of Food Science and Technology, College of Bioresources and Agriculture, National Taiwan University, Taipei, Taiwan.
Institute of Food Safety and Health, National Taiwan University, Taipei, Taiwan.
J Tradit Complement Med. 2024 May 16;15(1):24-35. doi: 10.1016/j.jtcme.2024.05.003. eCollection 2025 Jan.
(CM) and (AM) are medicinal mushrooms with potential applications in the treatment of mood disorders, including depression and anxiety. While research suggests that both CM and AM possess anti-inflammatory properties and hold potential for treating depression when administered separately, there is limited knowledge about their efficacy when combined in a formula, as well as the underlying mechanism involving the modulation of microglia.
Rats received oral administrations of the low-dose formulation, medium-dose formulation, and high-dose formulation over 28 consecutive days as part of the UCMS protocols. The concentrations of serotonin, dopamine, and the corresponding metabolites in the rat prefrontal cortex and hippocampus were assessed. Blood samples were collected to examine corticosterone levels, and the brains were dissected for evaluating activated microglia morphologies and associated pro- and anti-inflammatory signaling pathways.
The CM-AM formula effectively averted abnormal behaviors triggered by UCMS, such as anhedonia and hypoactivity, and decreased the turnover rate of monoamines in both the prefrontal cortex and hippocampus. The formula mitigated the increase in serum corticosterone levels induced by chronic stress. Furthermore, the formula alleviated stress-induced microglia activation in the hippocampus, achieving this by down-regulating hyperactivated pro-inflammatory proteins and up-regulating hypoactivated anti-inflammatory proteins in the hippocampus. The antidepressant-like effects potentially stemming from the regulation of neurotransmitters and immunomodulation, likely by restoring the balance of M1 and M2 microglia fractions in the hippocampus. Consequently, the CM-AM formula could be explored as a prospective complementary and alternative therapy for depression.
樟芝（CM）和云芝（AM）是具有潜在应用价值的药用真菌，可用于治疗包括抑郁症和焦虑症在内的情绪障碍。虽然研究表明CM和AM都具有抗炎特性，且单独给药时具有治疗抑郁症的潜力，但关于它们以配方形式联合使用时的疗效以及涉及小胶质细胞调节的潜在机制，人们了解有限。
作为慢性不可预测温和应激（UCMS）方案的一部分，大鼠连续28天口服低剂量配方、中剂量配方和高剂量配方。评估大鼠前额叶皮质和海马中血清素、多巴胺及其相应代谢物的浓度。采集血样以检测皮质酮水平，并解剖大脑以评估活化小胶质细胞的形态以及相关的促炎和抗炎信号通路。
CM-AM配方有效避免了UCMS引发的异常行为，如快感缺失和活动减退，并降低了前额叶皮质和海马中单胺的周转率。该配方减轻了慢性应激诱导的血清皮质酮水平升高。此外，该配方减轻了海马中应激诱导的小胶质细胞活化，其通过下调海马中过度活化的促炎蛋白和上调低活化的抗炎蛋白来实现。抗抑郁样作用可能源于神经递质调节和免疫调节，可能是通过恢复海马中M1和M2小胶质细胞比例的平衡。因此，CM-AM配方可作为抑郁症的一种潜在补充和替代疗法进行探索。
